Custom Monoclonal and Polyclonal Antibody Development
- Company Details
- Products & Services
- White Papers
- Press Releases
- Regional Offices
- Contact Company
Immunoprecise Antibodies Issues Letter to Shareholders
Life sciences technology and product company Immunoprecise has announced that its president Thomas D'Orazio has released a letter to shareholders to reflect on why he has also accepted the role...
ImmunoPrecise's Rapid Prime System Ensures a 65-Day Completion of Hybridoma Development Programs
As a leading provider of custom monoclonal and polyclonal antibody development with over 20 years of experience, ImmunoPrecise Antibodies is well-positioned to offer some of the fastest...